Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alectinib + nivolumab
- Development stage
- Preclinical
- Lead developer
- Chugai Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of alectinib, an ALK tyrosine kinase inhibitor, and nivolumab, a PD-1 immune checkpoint inhibitor. Alectinib targets the ALK fusion protein in ALK-positive non-small cell lung cancer (NSCLC), inhibiting ALK phosphorylation and downstream signaling. Nivolumab is a human IgG4 monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), enhancing T-cell immune response against tumor cells. This combination aims to simultaneously target cancer cells through ALK inhibition and enhance immune system recognition of cancer cells.
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on alectinib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alectinib + nivolumab.